Chong Kun Dang Pharmaceutical Corp
KRX:185750

Watchlist Manager
Chong Kun Dang Pharmaceutical Corp Logo
Chong Kun Dang Pharmaceutical Corp
KRX:185750
Watchlist
Price: 93 300 KRW 0.65%
Market Cap: 1.2T KRW
Have any thoughts about
Chong Kun Dang Pharmaceutical Corp?
Write Note

Chong Kun Dang Pharmaceutical Corp
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chong Kun Dang Pharmaceutical Corp
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Chong Kun Dang Pharmaceutical Corp
KRX:185750
Cost of Revenue
-â‚©1T
CAGR 3-Years
-7%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Cost of Revenue
-â‚©1.3T
CAGR 3-Years
2%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
SK Biopharmaceuticals Co Ltd
KRX:326030
Cost of Revenue
-â‚©34.1B
CAGR 3-Years
-158%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Cost of Revenue
-â‚©691.3B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Cost of Revenue
-â‚©109.5B
CAGR 3-Years
-12%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
C
Celltrion Pharm Inc
KOSDAQ:068760
Cost of Revenue
-â‚©323.1B
CAGR 3-Years
-10%
CAGR 5-Years
-22%
CAGR 10-Years
-31%
No Stocks Found

Chong Kun Dang Pharmaceutical Corp
Glance View

Market Cap
1.2T KRW
Industry
Pharmaceuticals

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-12-06. The firm is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The firm sells products in domestic and overseas markets.

Intrinsic Value
97 275.99 KRW
Undervaluation 4%
Intrinsic Value
Price

See Also

What is Chong Kun Dang Pharmaceutical Corp's Cost of Revenue?
Cost of Revenue
-1T KRW

Based on the financial report for Dec 31, 2023, Chong Kun Dang Pharmaceutical Corp's Cost of Revenue amounts to -1T KRW.

What is Chong Kun Dang Pharmaceutical Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-12%

Over the last year, the Cost of Revenue growth was -7%. The average annual Cost of Revenue growth rates for Chong Kun Dang Pharmaceutical Corp have been -7% over the past three years , -12% over the past five years .

Back to Top